RE
FHTX icon

RBC Europe’s Foghorn Therapeutics FHTX Stock Holding History

RBC Europe’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-860
Closed -$12K – 801
2021
Q3 		$12K Buy
860
+720
+514% +$7.97K ﹤0.01% 901
2021
Q2 		$1.49K Hold
140
– – ﹤0.01% 1156
2021
Q1 		$1.84K Hold
140
– – ﹤0.01% 1085
2020
Q4 		$2.84K Buy
+140
New +$2.68K ﹤0.01% 1027

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RBC Europe's FHTX Position: Q4 2021 in Review

RBC Europe sold out of Foghorn Therapeutics (FHTX) in Q4 2021, closing a stake of 860 shares — an estimated $12K sold.

RBC Europe first reported a position in FHTX in Q4 2020 and held it in 4 quarters. The position peaked at $12K in Q3 2021. 60 funds tracked by Wall St. Rank hold FHTX as of Q4 2021.

  • RBC Europe reported no remaining Foghorn Therapeutics position as of Q4 2021 after selling out during the quarter.
  • RBC Europe sold 860 Foghorn Therapeutics shares in Q4 2021, an estimated $12K.
  • RBC Europe first reported a position in Foghorn Therapeutics in Q4 2020 and held it in 4 quarters.
  • RBC Europe's Foghorn Therapeutics position peaked at $12K in Q3 2021.
  • 60 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.